These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25605014)

  • 1. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
    Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
    Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
    Labbé DP; Sweeney CJ; Brown M; Galbo P; Rosario S; Wadosky KM; Ku SY; Sjöström M; Alshalalfa M; Erho N; Davicioni E; Karnes RJ; Schaeffer EM; Jenkins RB; Den RB; Ross AE; Bowden M; Huang Y; Gray KP; Feng FY; Spratt DE; Goodrich DW; Eng KH; Ellis L
    Clin Cancer Res; 2017 Nov; 23(22):7072-7083. PubMed ID: 28899973
    [No Abstract]   [Full Text] [Related]  

  • 3. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
    Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
    PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor.
    Tamaichi H; Sato M; Porter AC; Shimizu T; Mizutani S; Takagi M
    Cancer Sci; 2013 Feb; 104(2):178-84. PubMed ID: 23163762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors.
    Panousis D; Patsouris E; Lagoudianakis E; Pappas A; Kyriakidou V; Voulgaris Z; Xepapadakis G; Manouras A; Athanassiadou AM; Athanassiadou P
    Eur J Gynaecol Oncol; 2011; 32(2):156-9. PubMed ID: 21614903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
    Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
    Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.
    de Resende MF; Vieira S; Chinen LT; Chiappelli F; da Fonseca FP; Guimarães GC; Soares FA; Neves I; Pagotty S; Pellionisz PA; Barkhordarian A; Brant X; Rocha RM
    J Transl Med; 2013 Feb; 11():36. PubMed ID: 23398928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 10. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
    Järvinen TA; Liu ET
    Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
    Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
    Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
    Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
    Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
    Arivazhagan A; Kumar DM; Sagar V; Patric IR; Sridevi S; Thota B; Srividya MR; Prasanna K; Thennarasu K; Mondal N; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
    J Neurooncol; 2012 Apr; 107(2):289-97. PubMed ID: 22102081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
    Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
    Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
    Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
    Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers.
    Ip JC; Pang TC; Glover AR; Soon P; Zhao JT; Clarke S; Robinson BG; Gill AJ; Sidhu SB
    Oncologist; 2015 Mar; 20(3):247-56. PubMed ID: 25657202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
    Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
    Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma.
    Wang N; Zhu M; Tsao SW; Man K; Zhang Z; Feng Y
    Mol Cancer; 2013 Oct; 12(1):119. PubMed ID: 24103454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
    Pourpak A; Landowski TH; Dorr RT
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2, an epigenetic driver of prostate cancer.
    Yang YA; Yu J
    Protein Cell; 2013 May; 4(5):331-41. PubMed ID: 23636686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.